Skip to content
Back to STOK

Stoke Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
79
Purchases
0
Sales
79
Purchase value
$0.00
Sale value
$7.88M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Barry TichoCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Nov 4, 2026Period of report Nov 2, 20260001780088-26-000025
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 2, 2026
Common StockF1F26,995$26.3779$184.51K12,064Direct
SaleNov 2, 2026
Common StockF1F3200$26.9913$5.40K11,864Direct
Filing footnotes · 3
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.91 to $26.87 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.96 to $27.03 per share, inclusive.
Open on SEC EDGAR
Jonathan AllanGENERAL COUNSEL & CORP SEC
4Rule 10b5-1 plan disclosed
Filed Oct 2, 2026Period of report Oct 2, 20260001966716-26-000014
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 2, 2026
Common StockF1627$26.33$16.51K20,598Direct
Filing footnotes · 1
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
Open on SEC EDGAR
Barry TichoCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Oct 2, 2026Period of report Oct 1, 20260001780088-26-000023
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 1, 2026
Common StockF1F21,051$26.1594$27.49K19,059Direct
Filing footnotes · 2
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.91 to $26.51 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Barry TichoCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Sep 3, 2026Period of report Sep 1, 20260001780088-26-000021
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 1, 2026
Common StockF1F23,945$30.512$120.37K21,710Direct
SaleSep 1, 2026
Common StockF1F31,600$31.0569$49.69K20,110Direct
Filing footnotes · 3
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.94 to $30.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.96 to $31.20 per share, inclusive.
Open on SEC EDGAR
Jonathan AllanGENERAL COUNSEL & CORP SEC
4
Filed Aug 18, 2026Period of report Aug 14, 20260001966716-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 18, 2026
Common StockF1F22,716$32.0072$86.93K21,370Direct
SaleAug 18, 2026
Common StockF1F3145$32.4681$4.71K21,225Direct
Filing footnotes · 5
  1. F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.
  4. F4Each performance stock unit represents a right to receive one share of the Issuer's common stock.
  5. F5Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
Open on SEC EDGAR
Barry TichoCHIEF MEDICAL OFFICER
4
Filed Aug 18, 2026Period of report Aug 14, 20260001780088-26-000019
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 18, 2026
Common StockF1F24,525$32.0072$144.83K25,897Direct
SaleAug 18, 2026
Common StockF1F3242$32.4681$7.86K25,655Direct
Filing footnotes · 5
  1. F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.
  4. F4Each performance stock unit represents a right to receive one share of the Issuer's common stock.
  5. F5Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
Open on SEC EDGAR
Edward M. MD KayeDirector
4
Filed Aug 18, 2026Period of report Aug 14, 20260001522780-26-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 18, 2026
Common StockF1F211,930$32.0072$381.85K125,194Direct
SaleAug 18, 2026
Common StockF1F3637$32.4681$20.68K124,557Direct
Filing footnotes · 5
  1. F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.
  4. F4Each performance stock unit represents a right to receive one share of the Issuer's common stock.
  5. F5Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
Open on SEC EDGAR
Barry TichoCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Aug 5, 2026Period of report Aug 3, 20260001780088-26-000017
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 3, 2026
Common StockF1F25,907$28.9501$171.01K21,691Direct
SaleAug 3, 2026
Common StockF1F31,269$29.4539$37.38K20,422Direct
Filing footnotes · 3
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.36 to $29.35 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.36 to $29.54 per share, inclusive.
Open on SEC EDGAR
Barry TichoCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Jul 6, 2026Period of report Jul 1, 20260001780088-26-000015
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 1, 2026
Common StockF1F26,728$32.615$219.43K28,098Direct
SaleJul 1, 2026
Common StockF1F3500$33.2678$16.63K27,598Direct
Filing footnotes · 3
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $33.05 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.23 to $33.37 per share, inclusive.
Open on SEC EDGAR
Jonathan AllanGENERAL COUNSEL & CORP SEC
4Rule 10b5-1 plan disclosed
Filed Jun 18, 2026Period of report Jun 16, 20260001966716-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 16, 2026
Common StockF11,457$29.95$43.64K18,086Direct
Filing footnotes · 1
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
Open on SEC EDGAR
Barry TichoCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Jun 3, 2026Period of report Jun 1, 20260001780088-26-000013
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 1, 2026
Common StockF11,795$30.58$54.89K34,826Direct
Filing footnotes · 1
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
Open on SEC EDGAR
Barry TichoCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed May 5, 2026Period of report May 1, 20260001780088-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 1, 2026
Common StockF12,243$32.79$73.55K36,621Direct
Filing footnotes · 1
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
Open on SEC EDGAR
Barry TichoCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Apr 3, 2026Period of report Apr 1, 20260001780088-26-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 1, 2026
Common StockF11,838$32.66$60.03K38,864Direct
Filing footnotes · 1
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
Open on SEC EDGAR
Jonathan AllanGENERAL COUNSEL & CORP SEC
4Rule 10b5-1 plan disclosed
Filed Mar 24, 2026Period of report Mar 20, 20260001966716-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 20, 2026
Common StockF1F28,692$33.6354$292.36K20,144Direct
SaleMar 20, 2026
Common StockF1F3601$34.4079$20.68K19,543Direct
Filing footnotes · 3
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.28 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.34 to $35.12 per share, inclusive.
Open on SEC EDGAR
Barry TichoCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Mar 19, 2026Period of report Mar 17, 20260001780088-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 19, 2026
Common StockF61,461$29.99$43.82K40,702Direct
SaleMar 18, 2026
Common StockF1F46,100$31.2838$190.83K41,384Direct
SaleMar 18, 2026
Common StockF1F5483$31.7888$15.35K40,901Direct
SaleMar 18, 2026
Common StockF1103$32.85$3.38K40,798Direct
SaleMar 17, 2026
Common StockF1F23,577$32.7394$117.11K50,071Direct
SaleMar 17, 2026
Common StockF1F32,587$33.3754$86.34K47,484Direct
Filing footnotes · 7
  1. F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.
  5. F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.
  6. F6This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
  7. F7The option is fully vested and exercisable.
Open on SEC EDGAR
Jonathan AllanGENERAL COUNSEL & CORP SEC
4
Filed Mar 19, 2026Period of report Mar 17, 20260001966716-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 18, 2026
Common StockF1F44,222$31.2838$132.08K29,242Direct
SaleMar 18, 2026
Common StockF1F5334$31.7888$10.62K28,908Direct
SaleMar 18, 2026
Common StockF172$32.85$2.37K28,836Direct
SaleMar 17, 2026
Common StockF1F22,476$32.7394$81.06K35,255Direct
SaleMar 17, 2026
Common StockF1F31,791$33.3754$59.78K33,464Direct
Filing footnotes · 5
  1. F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.
  5. F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.
Open on SEC EDGAR
Thomas LeggettChief Financial Officer
4
Filed Mar 19, 2026Period of report Mar 17, 20260001774690-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 18, 2026
Common StockF1F42,173$31.2838$67.98K10,381Direct
SaleMar 18, 2026
Common StockF1F5172$31.7888$5.47K10,209Direct
SaleMar 18, 2026
Common StockF137$32.85$1.22K10,172Direct
SaleMar 17, 2026
Common StockF1F21,274$32.7394$41.71K13,476Direct
SaleMar 17, 2026
Common StockF1F3922$33.3754$30.77K12,554Direct
Filing footnotes · 5
  1. F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.
  5. F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.
Open on SEC EDGAR
Jason HoittChief Patient Officer
4
Filed Mar 19, 2026Period of report Mar 17, 20260001762572-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 18, 2026
Common StockF1F41,762$31.2838$55.12K10,445Direct
SaleMar 18, 2026
Common StockF1F5139$31.7888$4.42K10,306Direct
SaleMar 18, 2026
Common StockF130$32.85$985.5010,276Direct
SaleMar 17, 2026
Common StockF1F21,033$32.7394$33.82K12,955Direct
SaleMar 17, 2026
Common StockF1F3748$33.3754$24.96K12,207Direct
Filing footnotes · 5
  1. F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.
  5. F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.
Open on SEC EDGAR
Arthur a LevinDirector
4Rule 10b5-1 plan disclosed
Filed Mar 17, 2026Period of report Mar 13, 20260001181556-26-000005
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 13, 2026
Common StockF1605$36.80$22.26K4,237Direct
Filing footnotes · 1
  1. F1The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2025.
Open on SEC EDGAR
Adrian R. KrainerDirector
4Rule 10b5-1 plan disclosed
Filed Mar 12, 2026Period of report Mar 10, 20260001780081-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 10, 2026
Common StockF1F233,243$39.7366$1.32M283,302Direct
Filing footnotes · 2
  1. F1The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.11 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Arthur TzianabosDirector · Interim Executive Chair
4Rule 10b5-1 plan disclosed
Filed Mar 12, 2026Period of report Mar 10, 20260001586226-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 10, 2026
Common StockF1F24,355$40.0033$174.21K31,339Direct
Filing footnotes · 3
  1. F1The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.095 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3Effective October 6, 2025, this option became fully vested and exercisable.
Open on SEC EDGAR
Adrian R. KrainerDirector
4Rule 10b5-1 plan disclosed
Filed Mar 4, 2026Period of report Mar 2, 20260001780081-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF1F27,229$39.6618$286.72K316,545Direct
Filing footnotes · 2
  1. F1The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.80 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Jonathan AllanGENERAL COUNSEL & CORP SEC
4Rule 10b5-1 plan disclosed
Filed Dec 10, 2025Period of report Dec 8, 20250001966716-25-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 8, 2025
Common StockF1F21,300$31.5956$41.07K14,509Direct
SaleDec 8, 2025
Common StockF1F32,678$32.6128$87.34K11,831Direct
Filing footnotes · 3
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.27 to $32.14 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.29 to $33.19 per share, inclusive.
Open on SEC EDGAR
Edward M. MD KayeDirector
4Rule 10b5-1 plan disclosed
Filed Dec 10, 2025Period of report Dec 8, 20250001522780-25-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 8, 2025
Common StockF1F23,825$31.4387$120.25K58,729Direct
SaleDec 8, 2025
Common StockF1F38,274$32.52$269.07K50,455Direct
SaleDec 8, 2025
Common StockF1F41,331$33.1041$44.06K49,124Direct
Filing footnotes · 4
  1. F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.90 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 2 and 3 of this Form 4.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.95 per share, inclusive.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.25 per share, inclusive.
Open on SEC EDGAR
Jonathan AllanGENERAL COUNSEL & CORP SEC
4Rule 10b5-1 plan disclosed
Filed Dec 5, 2025Period of report Dec 3, 20250001966716-25-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 5, 2025
Common StockF1F41,004$31.3304$31.46K23,590Direct
SaleDec 5, 2025
Common StockF5F65,437$31.0828$169.00K18,153Direct
SaleDec 5, 2025
Common StockF5F72,344$31.7597$74.44K15,809Direct
SaleDec 4, 2025
Common StockF1F2824$30.7635$25.35K24,788Direct
SaleDec 4, 2025
Common StockF1F3194$31.3164$6.08K24,594Direct
Filing footnotes · 9
  1. F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3, 4, 6, and 7 of this Form 4.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive.
  4. F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive.
  5. F5This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.
  6. F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.58 to $31.57 per share, inclusive.
  7. F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.59 to $31.97 per share, inclusive.
  8. F8Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
  9. F9Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
Open on SEC EDGAR
Barry TichoCHIEF MEDICAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Dec 5, 2025Period of report Dec 3, 20250001780088-25-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 5, 2025
Common StockF1F41,673$31.3304$52.42K21,787Direct
SaleDec 5, 2025
Common StockF51,989$31.3453$62.35K19,798Direct
SaleDec 4, 2025
Common StockF1F21,373$30.7635$42.24K23,783Direct
SaleDec 4, 2025
Common StockF1F3323$31.3164$10.12K23,460Direct
Filing footnotes · 7
  1. F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive.
  4. F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive.
  5. F5The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.
  6. F6Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
  7. F7Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
Open on SEC EDGAR
Edward M. MD KayeDirector
4Rule 10b5-1 plan disclosed
Filed Dec 5, 2025Period of report Dec 3, 20250001522780-25-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 5, 2025
Common StockF1F46,367$31.3304$199.48K64,735Direct
SaleDec 5, 2025
Common StockF5F61,681$31.1468$52.36K63,054Direct
SaleDec 5, 2025
Common StockF5F7500$31.846$15.92K62,554Direct
SaleDec 4, 2025
Common StockF1F25,222$30.7635$160.65K72,333Direct
SaleDec 4, 2025
Common StockF1F31,231$31.3164$38.55K71,102Direct
Filing footnotes · 9
  1. F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3, 4, 6, and 7 of this Form 4.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive.
  5. F5This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.
  6. F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.69 to $31.61 per share, inclusive.
  7. F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.70 to $31.96 per share, inclusive.
  8. F8Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
  9. F9Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
Open on SEC EDGAR
Jonathan AllanGENERAL COUNSEL & CORP SEC
4
Filed Dec 3, 2025Period of report Dec 1, 20250001966716-25-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 3, 2025
Common StockF1F4898$30.338$27.24K21,006Direct
SaleDec 3, 2025
Common StockF1F51,394$30.8477$43.00K19,612Direct
SaleDec 2, 2025
Common StockF1F21,416$29.562$41.86K22,772Direct
SaleDec 2, 2025
Common StockF1F3868$30.1419$26.16K21,904Direct
Filing footnotes · 7
  1. F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive.
  4. F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive.
  5. F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive.
  6. F6Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
  7. F733,927 restricted stock units from this award vested on December 1, 2024 and 12,357 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.
Open on SEC EDGAR
Barry TichoCHIEF MEDICAL OFFICER
4
Filed Dec 3, 2025Period of report Dec 1, 20250001780088-25-000005
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 3, 2025
Common StockF1F4789$30.338$23.94K16,381Direct
SaleDec 3, 2025
Common StockF1F51,225$30.8477$37.79K15,156Direct
SaleDec 2, 2025
Common StockF1F21,244$29.562$36.78K17,932Direct
SaleDec 2, 2025
Common StockF1F3762$30.1419$22.97K17,170Direct
Filing footnotes · 7
  1. F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive.
  4. F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive.
  5. F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive.
  6. F6Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
  7. F748,792 restricted stock units vested on December 1, 2024 and 11,981 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.
Open on SEC EDGAR
Edward M. MD KayeDirector
4
Filed Dec 3, 2025Period of report Dec 1, 20250001522780-25-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 3, 2025
Common StockF1F4419$30.338$12.71K51,956Direct
SaleDec 3, 2025
Common StockF1F5651$30.8477$20.08K51,305Direct
SaleDec 2, 2025
Common StockF1F2661$29.562$19.54K52,780Direct
SaleDec 2, 2025
Common StockF1F3405$30.1419$12.21K52,375Direct
Filing footnotes · 7
  1. F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5.
  3. F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive.
  4. F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive.
  5. F5The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive.
  6. F6Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
  7. F721,591 restricted stock units vested on December 1, 2024 and 4,317 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.
Open on SEC EDGAR
Adrian R. KrainerDirector
4Rule 10b5-1 plan disclosed
Filed Nov 26, 2025Period of report Nov 24, 20250001780081-25-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 24, 2025
Common StockF1F240,472$29.7173$1.20M323,774Direct
Filing footnotes · 2
  1. F1The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025.
  2. F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.12 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.